What is the current stock price of Arch Biopartners Inc. (ACHFF)?

As of the latest market data, Arch Biopartners Inc. (ACHFF) is trading at $0.35. The stock has seen a gain of 0.57% today.

Does Arch Biopartners Inc. (ACHFF) pay a dividend?

Based on current data, Arch Biopartners Inc. does not have a confirmed active dividend policy.

What is the market cap of Arch Biopartners Inc.?

The current market capitalization of Arch Biopartners Inc. (ACHFF) is approximately unavailable.

ACHFF

Arch Biopartners Inc.·Healthcare

0.35

0.571%(+0.00)

Close Price

Last Updated: — ET

52W L: $0.3352W H: $1.42

ACHFF NEWS

globenewswire.com

Apr 2

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”).

globenewswire.com

Mar 30

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 CAD per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”).

globenewswire.com

Mar 24

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement (“CTA”) with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

globenewswire.com

Mar 20

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael's Hospital (SMH), part of Unity Health Toronto, has commenced patient dosing in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

globenewswire.com

Feb 9

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary has published new data in the peer-reviewed journal Inflammation Research identifying interleukin-32 (IL-32) as a novel lipid droplet-associated cytokine that may contribute to tubular injury and inflammation in diabetic kidney disease (DKD).

Company Profile

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2002-04-24

Beta

2.05

Websitewww.archbiopartners.com↗